Low-dose Azacitidine and Venetoclax Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in High-risk AML and MDS Patients: Single Center Retrospective Analysis

Simple item page
dc.contributor.authorEdgar, Cory
dc.date.accessioned2023-06-25T19:27:45Z
dc.date.available2023-06-25T19:27:45Z
dc.date.issued2022
dc.identifier.citationEdgar, C. M., Clark, P., Patel, R. D., Varela, J. C., & Mori, S. (2022). Low-dose azacitidine and venetoclax maintenance following allogeneic hematopoietic stem cell transplantation in high-risk AML and MDS patients: Single center retrospective analysis. Transplantation and Cellular Therapy, 28(3), S434. https://doi.org/10.1016/S2666-6367(22)00717-5
dc.identifier.urihttps://doi.org/10.1016/S2666-6367(22)00717-5
dc.identifier.urihttps://hdl.handle.net/20.500.12521/482
dc.titleLow-dose Azacitidine and Venetoclax Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in High-risk AML and MDS Patients: Single Center Retrospective Analysis
dc.typePresentation

Files

Collections

Peer-Reviewed Resources Other Than Journal Articles